Why does luteal phase defect and low progesterone?
In clinical medicine, luteal phase defect and low progesterone is primarily driven by targeted biochemical, hormonal, or cellular signaling alterations. Contemporary peer-reviewed evidence indicates that comprehensive quantitative biomarker testing combined with multi-targeted clinical therapies (including pharmacotherapy and physiological lifestyle interventions) yields favorable clinical recovery rates. It is recommended to evaluate complete laboratory panels before initiating targeted intervention.